**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 62457

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Stem cell injection for complex anal fistula in Crohn’s disease: A single-center experience**

Schwandner O. Stem cells for anal Crohn’s fistula

Oliver Schwandner

**Oliver Schwandner,** Department of Proctology, Krankenhaus Barmherzige Brueder, Regensburg 93049, Germany

**Author contributions:** Schwandner O performed the research and wrote the paper.

**Corresponding author: Oliver Schwandner, FASCRS, MD, Professor,** Department of Proctology, Krankenhaus Barmherzige Brueder, Pruefeninger Str 86, Regensburg 93049, Germany. oliver.schwandner@barmherzige-regensburg.de

**Received:** January 9, 2021

**Revised:** March 10, 2021

**Accepted:** June 4, 2021

**Published online:** June 28, 2021

**Abstract**

BACKGROUND

Despite tremendous progress in medical therapy and optimization of surgical strategies, considerable failure rates after surgery for complex anal fistula in Crohn’s disease have been reported. Therefore, stem cell therapy for the treatment of complex perianal fistula can be an innovative option with potential long-term healing.

AIM

To evaluate the results of local administration of allogenic, adipose-derived mesenchymal stem cells (darvadstrocel) for complex anal Crohn’s fistula.

METHODS

All patients with complex anal fistulas associated with Crohn’s disease who were amenable for definite fistula closure within a defined observation period were potential candidates for stem cell injection (darvadstrocel) if at least one conventional or surgical attempt to close the fistula had failed. Darvadstrocel was only indicated in patients without active Crohn’s disease and without presence of anorectal abscess. Local injection of darvadstrocel was performed as a standardized procedure under general anesthesia including single-shot antibiotic prophylaxis, removal of seton drainage, fistula curettage, closure of the internal openings and local stem cell injection. Data collection focusing on healing rates, occurrence of abscess and follow-up was performed on a regular basis of quality control and patient care. Data were retrospectively analyzed.

RESULTS

Between July 2018 and January 2021, 12 patients (6 females, 6 males) with a mean age of 42.5 (range: 26-61) years underwent stem cell therapy. All patients had a minimum of one complex fistula, including patients with two complex fistulas in 58.3% (7/12). Two of the 12 patients had horse-shoe fistula and 3 had one complex fistula. According to Parks classification, the majority of fistulas were transsphincteric (76%) or suprasphincteric (14%). All patients underwent removal of seton, fistula curettage, transanal closure of internal opening by suture (11/12) or mucosal flap (1/12) and stem cell injection. At a mean follow-up of 14.3 (range: 3-30) mo, a healing rate was documented in 66.7% (8/12); mean duration to achieve healing was 12 (range: 6-30) wk. Within follow-up, 4 patients required reoperation due to perianal abscess (33.3%). Focusing on patients with a minimum follow-up of 12 mo (6/12) or 24 mo (4/12), long-term healing rates were 66.7% (4/6) and 50.0% (2/4), respectively.

CONCLUSION

Data of this single-center experience are promising but limited due to the small number of patients and the retrospective analysis.

**Key Words:** Complex anal fistula; Crohn’s disease; Stem cell therapy; Mesenchymal stem cells; Darvadstrocel; Treatment; Surgery; Outcomes

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Schwandner O. Stem cell injection for complex anal fistula in Crohn’s disease: A single-center experience. *World J Gastroenterol* 2021; 27(24): 3643-3653

**URL:** https://www.wjgnet.com/1007-9327/full/v27/i24/3643.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v27.i24. 3643

**Core Tip:** This is a retrospective single-center study on the application of allogenic, adipose-derived mesenchymal stem cells (darvadstrocel) for complex perianal fistula associated with Crohn’s disease, providing structured inclusion and exclusion criteria for 12 patients. The current data demonstrate that the management by local stem cell therapy is safe and effective. However, based on the small patient sample size and the retrospective analysis of routine clinical data, a general conclusion remains limited. Therefore, further prospective controlled studies are mandatory to assess the definite role of adipose-derived mesenchymal stem cells for complex anal fistula in Crohn’s disease.

**INTRODUCTION**

Both medical and surgical options for complex perianal fistulas associated with Crohn’s disease remain difficult and challenging[1-5]. Despite recent progress in medical treatment including biologicals and actual trends in sphincter-preserving surgical techniques, considerable recurrence rates after definite surgery for Crohn’s anal fistula have been documented[2,3,5]. As an interdisciplinary treatment regimen is the prerequisite for disease control and potential long-term remission of perianal fistulizing Crohn’s disease, therapeutic goals include symptom improvement (*e.g*., reduction of secretion, absence of pain), prevention of recurrent perianal abscess requiring further surgery, preservation of continence, improvement of quality of life and, finally, healing of the fistula.

Focusing on surgical procedures for complex anal fistulas, conventional procedures such as advancement flap repair have shown considerable failure rates for Crohn’s fistulas, whereas innovative surgical options such as ligation of the intersphincteric fistula tract (LIFT), biomaterials (*e.g*., plug) or video-assisted anal fistula treatment seem to have a 50% healing rate after 12 mo without significant impairment of continence[6]. Recently, several reports and randomized studies have demonstrated that stem cell therapy for Crohn’s complex anal fistula has raised the healing rates after 12 mo[2,7,8].

Impressed by the encouraging healing rates reported from the ADMIRE trial[7,8], it was the aim of this retrospective single-center study to evaluate the current results of stem cell therapy for complex anal fistulas in Crohn’s disease with special focus on indication, patient selection and long-term outcome.

**MATERIALS AND METHODS**

***Clinical setting***

Stem cell injection was performed by administration of human, allogenic, expanded adipose-derived mesenchymal stem cells (darvadstrocel) for complex anal fistulas associated with Crohn’s disease in adult patients. For the current study, Alofisel® (5 million cells/mL) was used (Takeda GmbH, Konstanz, Germany). Upon authorization of the European Medicines Agency (initial authorization on December 14, 2017), Alofisel® is indicated in patients with non-active or mildly active Crohn’s disease when fistulas show an inadequate response (failure either due to persistence or recurrence) to at least one conventional, biological or surgical therapy. Darvadstrocel was only administered if the fistulas had conditioning by curettage or seton drainage. All potential candidates for stem cell injection had fully informed consent of the innovative method and underwent a selection process by multidisciplinary evaluation and discussion (gastroenterology and proctology); finally, the center was trained by an educational and hands-on workshop for the use of darvadstrocel in complex fistulas in Crohn’s disease to ensure that only specialist physicians perform the procedure. Moreover, intrainstitutional education was conducted for darvadstrocel administration (*e.g*., pharmacy, surgical team).

***Study population***

All patients with complex anorectal fistulas associated with Crohn’s disease who were amenable for definite fistula closure were potential candidates for darvadstrocel administration if at least one conventional or surgical attempt to close the fistula had failed. All patients suffered from complex fistula according to American Gastroenterological Association and Parks classification[9,10]. All patients had a minimum of one complex fistula, including patients with two complex fistulas in 58.3% (7/12). According to Parks classification, 76% of the fistulas were transsphincteric and 14% were suprasphincteric. Darvadstrocel was only indicated in patients without active Crohn’s disease, ruled out by ileocolonoscopy, and without the presence of anorectal abscess assessed by clinical examination and/or pelvic magnetic resonance imaging (MRI). Additionally, all patients had interdisciplinary discussion prior to surgical treatment. Specific inclusion and exclusion criteria are outlined in Table 1.

***Study design and outcome evaluation***

To evaluate the outcome of patients who underwent local stem cell injection by the application of darvadstrocel, a retrospective analysis of existing routine clinical data was performed. In detail, regular clinical data of patient care and quality control (including patients’ characteristics, type of therapy, outcome evaluation during routine clinical follow-up) were retrospectively analyzed in an anonymized fashion. Patients underwent darvadstrocel administration not for primary study purpose but for quality assurance and patient care. To assess outcome, criteria of healing included that both internal and external openings were closed, no abscess or fluid collection was present and if the patient was free of symptoms (*e.g*., pain, secretion). Healing was assessed by clinical examination and proctoscopy. Strict criteria and definitions of persistence and recurrence are outlined in Table 2.

***Special consideration for coronavirus disease 2019 pandemic***

Due to the coronavirus disease pandemic in the beginning of 2020, the coronavirus disease 2019 (COVID-19) outbreak had direct implications for patients with perianal fistulizing Crohn’s disease regarding their schedule for definite surgery. As a result of the primary outbreak in March 2020, no patients had elective surgery for Crohn’s associated complex anal fistulas at our institution between March 2020 and July 2020 according to governmental restrictions (German Ministry of Health). Moreover, according to a second restriction period for elective procedures at our institution starting in November 2020, potential procedures were postponed to 2021. Finally, a relevant number of patients with fistulizing perianal Crohn’s disease under immunosuppression and/or maintenance therapy (*e.g*., biologicals) postponed their surgery to 2021.

***Preoperative assessment***

All patients amenable for stem cell injection were seen in the proctological office 2-4 wk prior to darvadstrocel treatment. Informed consent was given, including for efficacy from the ADMIRE study, innovation of the current technique, and monitoring of side effects or adverse events, surgical technique and follow-up observation. Proctological examination included clinical examination and proctorectoscopy to rule out abscess or proctitis in the immediate preoperative phase. No antibiotic treatment was administered; setons were controlled to be correct in place. No routine curettage of fistulas drained by setons was performed in the preoperative period, and no specific change for medical treatment was performed.

***Surgical technique***

All surgical procedures were performed under general anesthesia. The patient was placed in lithotomy position. A single-shot antibiotic prophylaxis was routinely administered (cefuroxime/metronidazole). Initially, a careful examination under anesthesia was performed to ensure that there was no presence of abscess or proctitis; moreover, assessment of fistula length, anatomy and topography according to Parks classification[10] was performed. After removal of setons, a vigorous curettage of the fistula tracts was performed by using a metallic curette. Additionally, injection of a sodium chloride solution (0.9%) was administered after curettage. No excision of the fistula tracts were conducted; however, the external openings were sparingly excised. Afterwards, the internal openings were closed by either direct suturing (absorbable suture, Vicryl 3/0; Ethicon EndoSurgery, Norderstedt, Germany) or by mucosal flap (absorbable suture, Vicryl 3/0) if necessary.

After preparing and resuspension of the stem cells and gentle aspiration by using a syringe and injection needles (22-G), darvastrocel was injected according to the manufacturer`s recommendations: Two vials were injected around the internal openings (transanal approach), and the other two vials were injected along the fistula tracts creating small deposits of the cell suspension along the fistulas from external openings (perianal approach). After injection, a soft massage along the fistula region was performed; finally, a sterile bandage was placed around the anal region.

Postoperatively, no specific restrictions related to feeding and mobility were present; after wound control on the first postoperative day, the patient was discharged from hospital. No specific wound management was proposed (only clear water twice a day). Maintenance therapy was given as planned prior to surgery. Neither intravenous nor oral antibiotic therapy was given in the postoperative period.

***Follow-up***

Regular follow-up examination was performed 2, 4 and 6 wk after surgery in the proctological office, to obtain clinical data related to quality assurance and patient care. Moreover, follow-up examination was advised at 6, 12 and 24 mo after stem cell injection. Additionally, gastroenterological monitoring was advised to provide regular monitoring of Crohn’s disease. As clinical follow-up was primarily indicated for routine quality control and was not indicated for study purpose, regular follow-up did not include postoperative MRI as routine examination.

**RESULTS**

***Study population and patient characteristics***

Between July 2018 and January 2021, a total of 12 patients (6 females, 6 males) with a mean age of 42.5 (range: 26-61) years underwent stem cell therapy for complex anal fistula associated with Crohn’s disease. All patients had medical therapy (infliximab, adalimumab, vedolizumab or azathioprine), and complex fistulas did not respond to either medical or surgical treatment prior to stem cell therapy. Mean duration of Crohn’s disease was 19.3 years (range: 7-36 years), and median duration of perianal fistulizing Crohn’s disease was 8.7 years (range: 1-16 years). All fistulas had at least one conventional surgical approach to close the fistula (except seton drainage) prior to stem cell therapy; mean number of surgical attempts to close the fistula was 2.0 (range: 1-4). Details on study population and patients’ characteristics are detailed in Table 3.

***Fistula characterization***

All patients underwent fistula conditioning by seton drainage for a mean duration of 31.5 (range: 6-72) wk, and 4 patients had undergone fecal diversion due to severe perianal sepsis. All patients had a minimum of one complex fistula, including patients with two complex fistulas in 58.3% (7/12). Two of 12 patients had horse-shoe fistula, and 3 of 12 had one complex fistula. In total, 21 fistula tracts were documented in 12 patients. According to Parks classification, the majority of fistulas were transsphincteric (76%) or suprasphincteric (14%).

***Surgery***

All patients underwent removal of seton, fistula curettage, transanal closure of internal opening by suture (11/12) or mucosal flap (1/12) and stem cell injection. No intraoperative complications or side effects were noted. Postoperative morbidity included 1 patient with fewer (without signs of perianal sepsis) on the second postoperative day. No serious adverse events were documented.

***Outcome***

Details on efficacy evaluation and outcome are outlined in Table 4. At a mean follow-up of 14.3 mo (range: 3-30 mo), a healing rate was documented in 66.7% (8/12); mean duration to achieve healing was 12 wk (range: 6-30 wk). Four patients had either fistula persistence (*n* = 2, 16.7%) or fistula recurrence (*n* = 2; 16.7%). Within follow-up, 4 patients developed perianal abscess (33.3%) and required reoperation. From 4 patients with ileostomy, one stoma reversal was performed 2 years after fistula healing.

Focusing on patients with a minimum follow-up of 12 mo (6/12) or 24 mo (4/12), long-term healing rates were 66.7% (4/6) and 50.0% (2/4), respectively.

**DISCUSSION**

Despite significant progress in medical treatment, including biologicals and cell-based therapies, development of sphincter-saving surgical techniques and interdisciplinary co-working, failure rates after definite surgery for perianal fistulizing Crohn’s disease are still high[3,11-13]. Moreover, in patients with severe and refractory perianal disease, the decision to perform fecal diversion or even proctectomy has a tremendous impact on quality of life, particularly in younger patients. Impressed by the preliminary results of limited single-center studies and the encouraging data of the ADMIRE study[7,8], this was a retrospective single-center study analyzing routine clinical data on the application of allogenic, adipose-derived mesenchymal stem cells (darvadstrocel) for complex perianal fistula associated with Crohn’s disease, providing structured inclusion and exclusion criteria in 12 patients.

In general, the optimal surgical treatment of complex anal fistulas in patients with Crohn’s disease remains challenging. As the majority of patients need surgery for perianal fistulizing Crohn’s disease and a high proportion of patients need further surgery due to abscess and recurrent fistula, the integrity of the anal sphincter is essential for preservation of continence[3]. Therefore, the risk of deterioration of continence status increases with the number of surgical procedures and the invasiveness of procedures performed. For complex anal fistulas according to American Gastroenterological Association and Parks classification[9,10], transrectal flap procedures (advancement or mucosal flap repair) and the LIFT procedure can be considered as effective surgical options in stable disease and absence of proctitis and/or anorectal stenosis with acceptable healing rates[11-18]; however, fecal incontinence and soiling is reported in approximately 10% of patients after endorectal flap procedures[6,11,18]. Focusing on the LIFT procedure, the risk of incontinence is low, but about half of the patients need additional surgery due to recurrence[14-16]. The main “disadvantage” or limitation of both procedures are high complex fistulas with suprasphincteric course or multi-tract fistulas with two internal and external openings (“multiple branching tracts”). In these patients, long-term seton drainage is the favored option; alternatively, proctectomy can be considered. Based on this “surgical dilemma”, the novel therapeutic approach of local stem cell therapy seems to be an alternative for highly selected patients with multi-tract, complex fistulas.

In the meantime, a variety of limited studies demonstrated that local injection of mesenchymal stem cells can induce long-term fistula healing without the risk of incontinence and without serious adverse advents related to the mesenchymal stem cells themselves[19-22]. Following the results of the multicenter, phase III randomized control trial (ADMIRE), the application of allogenic, adipose-derived, mesenchymal stem cells combined with transanal closure of the internal opening and fistula curettage, a 50% healing rate of stem cell therapy compared with a 34% success in the placebo group was documented after 24 wk, and healing rates were sustained to 52 wk[7,8].

Impressed by these results and personally searching for the “best option” in patients with multi-branching or two-tract complex fistula, it was the aim of the current single-center experience to evaluate the outcome of local injection of darvadstrocel in a highly selected group of patients. Following the current single-center experience with stem cell therapy, strict inclusion and exclusion criteria were defined. In accordance with the inclusion criteria of the ADMIRE study[7,8], only patients with complex fistulas associated with Crohn’s disease–in the majority two complex fistula, suprasphincteric fistula and horse-shoe-fistula, without active luminal Crohn’s disease (stable disease under medical treatment) and no evidence of perianal sepsis were included. In contrast, simple fistulas or rectovaginal fistulas were excluded for stem cell therapy. Moreover, in the current study, patients with single-tract intersphincteric or transsphincteric fistulas as well as relatively short single-tract fistulas (fistula length less than 3 cm) were not candidates for stem cell therapy; in these patients, advancement flap repair, mucosal flap repair or LIFT procedure was the preferred option. Within the observation period, a total of 28 patients underwent flap or LIFT procedure for complex fistula associated with Crohn’s disease (data not shown).

All patients had drainage of fistulas by seton for a minimum of 6 wk. In contrast to the ADMIRE study[7,8], 4 patients who underwent fecal diversion due to perianal sepsis related to complex fistulas years before admission to our center were included in the current study after interdisciplinary discussion, as the only alternative surgical treatment would have been a proctectomy in these patients, and patients refused this option. Finally, all 12 patients had at least one attempt to surgically close the fistula with no success; thus, all fistulas treated with stem cell therapy were recurrent complex fistula.

Focusing on surgical technique and administration of darvadstrocel, no difficulties or intraoperative morbidity were documented. One patient had fewer on the second postoperative day without any signs of perianal sepsis. No serious adverse events in the immediate postoperative course were noted.

After a mean follow-up of 14.3 mo (range: 3-30 mo), healing rate was 66.7% (8 of 12 patients). Healing was based on strict criteria and was assessed by clinical examination and proctoscopy in the follow-up period. In terms of postoperative MRI (5/12 patients), 1 female patient with clinical evidence of fistula healing also had radiological healing as documented by MRI, whereas 3 patients had radiological recurrence (2) or persistence (1). One patient with clinical healing had radiologic persistence of fistula without signs of contrast enhancement. Focusing on patients with a minimum follow-up of 12 mo (6/12) or 24 mo (4/12), long-term healing rates were 66.7% (4/6) and 50.0% (2/4), respectively.

The occurrence of perianal abscess during follow-up was relatively frequent in the current collective. Four patients (33.3%) developed perianal abscess in the postoperative course, and surgery (abscess excision) was required (1 patient had abscess formation twice). Interestingly, the occurrence of perianal abscess was late (3, 4, 7, 9 and 22 mo after darvadstrocel administration), and abscess localization was near to one former external opening. The incidence of abscess was related to recurrence in 1 patient (supralevatoric abscess with proctosigmoiditis), occurred with exacerbation of systemic disease (subcutaneous abscess with active inflammation of ileocolic region and proctitis), and was associated with fistula persistence in 2 patients. As a consequence of the relatively high incidence of perianal abscess following stem cell therapy in the current series, a more wide or radical excision of the external opening should be recommended in future procedures to prevent perianal abscess. Moreover, patients with the occurrence of abscess could not be defined “in remission”; however, there was no change in medical treatment. Therefore, the differentiation of abscess as a local problem following fistula surgery or as a problem of systemic disease with direct implications for medical treatment should be more in focus between gastroenterologists and surgeons.

Analyzing the further course of patients with long-term healing in terms of medical therapy, 1 patient had ceased maintenance therapy after recommendation of the gastroenterologist. Focusing on patients who had fecal diversion in the past, one female patient underwent stoma reversal 2 years after stem cell injection. In the other 3 patients, follow-up is still too short, as stoma reversal should be advised not prior to a minimum period of 6 mo after definite fistula surgery (1 patient), and the other two patients had recurrence.

Specifically addressing the observation period related to the COVID-19 pandemic, stem cell therapy was not performed within March 2020 and July 2020 and within a second period starting in November 2020 due to general restrictions concerning elective operations in Germany. Based on governmental restrictions and in-hospital limitations (*e.g.*, reduced capacity in the surgical theater) as well as logistic reasons (*e.g.*, transportation of stem cells under specific conditions) patients with stable disease and without signs of active perianal disease were postponed. This was in accordance with other European and United States experiences related to the management of patients with inflammatory bowel disease[23,24].

The current results clearly demonstrate that an innovative sphincter-sparing surgical approach including fistula curettage, transanal closure of internal openings and local injection of darvadstrocel leads to promising long-term healing rates in patients with no “effective” alternative, such as flap repair or LIFT procedure. However, fundamental limitations of this single-center experience are the small number of patients, the retrospective design, and the absence of a control group. Therefore, the definite role of local application of mesenchymal stem cells has to be discussed within multidisciplinary round tables or consensus conferences to have clear position statements[25-28]. Actually, we are still in the episode of a “learning curve” in terms of patient selection, ideal surgical technique, interdisciplinary treatment discussion, role of maintenance therapy and evaluation of outcomes, among others. Therefore, generally accepted indications and pathways of stem cell therapy for complex fistulas in Crohn’s disease cannot be derived; however, the current results should be a plea for further standardization and interdisciplinary consensus.

**CONCLUSION**

These single-center data demonstrate that local injection of adipose-derived mesenchymal stem cells (darvadstrocel) is safe and effective in patients suffering from perianal fistulizing Crohn’s disease. Providing long-term healing in 66.7% of patients, stem cell therapy seems to be an innovative and promising surgical therapy for complex anal fistula associated with Crohn’s disease. However, this single-center experience is limited due to the small number of patients and the retrospective assessment of routine clinical data related to quality control. As a technical consequence of a high incidence of perianal abscess during follow-up, a wide excision of the external opening should be recommended for future procedures. Finally, further interdisciplinary efforts including controlled studies are necessary to evaluate the definite role of stem cell therapy for complex anal fistula in Crohn’s disease.

**ARTICLE HIGHLIGHTS**

***Research background***

Despite significant progress in medical therapy and surgical options, definite surgery for complex anal fistula in Crohn’s disease remains challenging.

***Research motivation***

At present, failure rates after surgery for complex anal fistula associated with Crohn’s disease are still high, and surgical options in patients with recurrent and/or multi-tract fistula are limited.

***Research objectives***

The primary objective was to assess whether local stem cell injection is associated with acceptable healing rates in a routine clinical setting.

***Research methods***

Providing strict inclusion and exclusion criteria, 12 patients with complex anal fistulas associated with Crohn’s disease underwent local application of allogenic, adipose-derived mesenchymal stem cells (darvadstrocel). Darvadstrocel was only indicated in patients without active Crohn’s disease confirmed by ileocolonoscopy and without presence of anorectal abscess. Study design was retrospective and routine clinical data were analyzed.

***Research results***

Twelve patients (6 females, 6 males) with complex anal fistula associated with Crohn’s disease underwent fistula curettage, transanal closure of internal openings and local darvadstrocel administration. Fifty-eight percent of patients had two complex fistulas, and seventy-six percent of the fistulas were transsphincteric. After a mean follow-up of 14.3 mo, a healing rate of 66.7% (8/12) was documented. Perianal abscess occurred in 33.3% of patients during follow-up.

***Research conclusions***

This single-center experience demonstrates that local stem cell injection for complex perianal fistulizing disease is safe and provides acceptable healing rates. However, conclusions are limited due to the small number of patients and the retrospective study design.

***Research perspectives***

Based on the current results, local stem cell injection could be a new “puzzle piece” for effective treatment of complex anal fistulas associated with Crohn’s disease.

**REFERENCES**

1 **Kelley KA**, Kaur T, Tsikitis VL. Perianal Crohn's disease: challenges and solutions. *Clin Exp Gastroenterol* 2017; **10**: 39-46 [PMID: 28223835 DOI: 10.2147/CEG.S108513]

2 **Panes J**, Reinisch W, Rupniewska E, Khan S, Forns J, Khalid JM, Bojic D, Patel H. Burden and outcomes for complex perianal fistulas in Crohn's disease: Systematic review. *World J Gastroenterol* 2018; **24**: 4821-4834 [PMID: 30479468 DOI: 10.3748/wjg.v24.i42.4821]

3 **Lightner AL**. Perianal Crohn's Disease. *Dis Colon Rectum* 2020; **63**: 1023-1026 [PMID: 32692067 DOI: 10.1097/DCR.0000000000001748]

4 **Scharl M**, Rogler G. Pathophysiology of fistula formation in Crohn's disease. *World J Gastrointest Pathophysiol* 2014; **5**: 205-212 [PMID: 25133023 DOI: 10.4291/wjgp.v5.i3.205]

5 **de Groof EJ**, Sahami S, Lucas C, Ponsioen CY, Bemelman WA, Buskens CJ. Treatment of perianal fistula in Crohn's disease: a systematic review and meta-analysis comparing seton drainage and anti-tumour necrosis factor treatment. *Colorectal Dis* 2016; **18**: 667-675 [PMID: 26921847 DOI: 10.1111/codi.13311]

6 **Schwandner O**. [Quality indicators in the treatment of anal fistulas]. *Chirurg* 2019; **90**: 270-278 [PMID: 30683947 DOI: 10.1007/s00104-019-0794-7]

7 **Panés J**, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Leselbaum A, Danese S; ADMIRE CD Study Group Collaborators. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. *Lancet* 2016; **388**: 1281-1290 [PMID: 27477896 DOI: 10.1016/S0140-6736(16)31203-X]

8 **Panés J**, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Diez MC, Tagarro I, Leselbaum A, Danese S; ADMIRE CD Study Group Collaborators. Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. *Gastroenterology* 2018; **154**: 1334-1342.e4 [PMID: 29277560 DOI: 10.1053/j.gastro.2017.12.020]

9 **Sandborn WJ**, Fazio VW, Feagan BG, Hanauer SB; American Gastroenterological Association Clinical Practice Committee. AGA technical review on perianal Crohn's disease. *Gastroenterology* 2003; **125**: 1508-1530 [PMID: 14598268 DOI: 10.1016/j.gastro.2003.08.025]

10 **Parks AG**, Gordon PH, Hardcastle JD. A classification of fistula-in-ano. *Br J Surg* 1976; **63**: 1-12 [PMID: 1267867 DOI: 10.1002/bjs.1800630102]

11 **Emile SH**, Elfeki H, Shalaby M, Sakr A. A Systematic review and meta-analysis of the efficacy and safety of video-assisted anal fistula treatment (VAAFT). *Surg Endosc* 2018; **32**: 2084-2093 [PMID: 29052068 DOI: 10.1007/s00464-017-5905-2]

12 **Guizzetti L**, Zou G, Khanna R, Dulai PS, Sandborn WJ, Jairath V, Feagan BG. Development of Clinical Prediction Models for Surgery and Complications in Crohn's Disease. *J Crohns Colitis* 2018; **12**: 167-177 [PMID: 29028958 DOI: 10.1093/ecco-jcc/jjx130]

13 **Sugrue J**, Mantilla N, Abcarian A, Kochar K, Marecik S, Chaudhry V, Mellgren A, Nordenstam J. Sphincter-Sparing Anal Fistula Repair: Are We Getting Better? *Dis Colon Rectum* 2017; **60**: 1071-1077 [PMID: 28891851 DOI: 10.1097/DCR.0000000000000885]

14 **Malakorn S**, Sammour T, Khomvilai S, Chowchankit I, Gunarasa S, Kanjanasilp P, Thiptanakij C, Rojanasakul A. Ligation of Intersphincteric Fistula Tract for Fistula in Ano: Lessons Learned From a Decade of Experience. *Dis Colon Rectum* 2017; **60**: 1065-1070 [PMID: 28891850 DOI: 10.1097/DCR.0000000000000880]

15 **Rojanasakul A**. LIFT procedure: a simplified technique for fistula-in-ano. *Tech Coloproctol* 2009; **13**: 237-240 [PMID: 19636496 DOI: 10.1007/s10151-009-0522-2]

16 **Sirany AM**, Nygaard RM, Morken JJ. The ligation of the intersphincteric fistula tract procedure for anal fistula: a mixed bag of results. *Dis Colon Rectum* 2015; **58**: 604-612 [PMID: 25944433 DOI: 10.1097/DCR.0000000000000374]

17 **Schwandner O**. Video-assisted anal fistula treatment (VAAFT) combined with advancement flap repair in Crohn's disease. *Tech Coloproctol* 2013; **17**: 221-225 [PMID: 23179892 DOI: 10.1007/s10151-012-0921-7]

18 **Soltani A**, Kaiser AM. Endorectal advancement flap for cryptoglandular or Crohn's fistula-in-ano. *Dis Colon Rectum* 2010; **53**: 486-495 [PMID: 20305451 DOI: 10.1007/DCR.0b013e3181ce8b01]

19 **Zabot GP**, Cassol O, Saad-Hossne R, Bemelman W. Modern surgical strategies for perianal Crohn's disease. *World J Gastroenterol* 2020; **26**: 6572-6581 [PMID: 33268947 DOI: 10.3748/wjg.v26.i42.6572]

20 **Garcia-Olmo D**, Guadalajara H, Rubio-Perez I, Herreros MD, de-la-Quintana P, Garcia-Arranz M. Recurrent anal fistulae: limited surgery supported by stem cells. *World J Gastroenterol* 2015; **21**: 3330-3336 [PMID: 25805941 DOI: 10.3748/wjg.v21.i11.3330]

21 **Dailey FE**, Turse EP, Naseer M, Bragg JD, Tahan V. Review of stem cells as promising therapy for perianal disease in inflammatory bowel disease. *World J Transplant* 2018; **8**: 97-101 [PMID: 30148075 DOI: 10.5500/wjt.v8.i4.97]

22 **Turse EP**, Dailey FE, Naseer M, Partyka EK, Tahan V. One more chance of fistula healing in inflammatory bowel disease: Stem cell therapy. *World J Clin Cases* 2018; **6**: 493-500 [PMID: 30397605 DOI: 10.12998/wjcc.v6.i12.493]

23 **Remzi FH**, Panis Y, Spinelli A, Kotze PG, Mantzaris G, Söderholm JD, d'Hoore A, Bemelman WA, Yamamoto T, Pemberton JH, Tiret E, Øresland T, Fleshner P. International Organization for the Study of IBD Recommendations for Surgery in Patients With IBD During the Coronavirus Disease 2019 Pandemic. *Dis Colon Rectum* 2020; **63**: 870-873 [PMID: 32355056 DOI: 10.1097/DCR.0000000000001718]

24 **Carlson GL**. Prioritizing Access to Surgical Care During the Coronavirus Pandemic. *Dis Colon Rectum* 2020; **63**: 879-880 [PMID: 32251144 DOI: 10.1097/DCR.0000000000001698]

25 **Horaist C**, de Parades V, Abramowitz L, Benfredj P, Bonnaud G, Bouchard D, Fathallah N, Sénéjoux A, Siproudhis L, Staumont G, Viguier M, Marteau P. Elaboration and validation of Crohn's disease anoperineal lesions consensual definitions. *World J Gastroenterol* 2017; **23**: 5371-5378 [PMID: 28839437 DOI: 10.3748/wjg.v23.i29.5371]

26 **Pellino G**, Keller DS, Sampietro GM, Annese V, Carvello M, Celentano V, Coco C, Colombo F, Cracco N, Di Candido F, Franceschi M, Laureti S, Mattioli G, Pio L, Sciaudone G, Sica G, Villanacci V, Zinicola R, Leone S, Danese S, Spinelli A, Delaini G, Selvaggi F; the Italian Society of Colorectal Surgery (SICCR). Inflammatory bowel disease (IBD) position statement of the Italian Society of Colorectal Surgery (SICCR): general principles of IBD management. *Tech Coloproctol* 2020; **24**: 105-126 [PMID: 31983044 DOI: 10.1007/s10151-019-02145-0]

27 **Lightner AL**, Vogel JD, Carmichael JC, Keller DS, Shah SA, Mahadevan U, Kane SV, Paquette IM, Steele SR, Feingold DL. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Crohn's Disease. *Dis Colon Rectum* 2020; **63**: 1028-1052 [PMID: 32692069 DOI: 10.1097/DCR.0000000000001716]

28 **Adamina M**, Bonovas S, Raine T, Spinelli A, Warusavitarne J, Armuzzi A, Bachmann O, Bager P, Biancone L, Bokemeyer B, Bossuyt P, Burisch J, Collins P, Doherty G, El-Hussuna A, Ellul P, Fiorino G, Frei-Lanter C, Furfaro F, Gingert C, Gionchetti P, Gisbert JP, Gomollon F, González Lorenzo M, Gordon H, Hlavaty T, Juillerat P, Katsanos K, Kopylov U, Krustins E, Kucharzik T, Lytras T, Maaser C, Magro F, Marshall JK, Myrelid P, Pellino G, Rosa I, Sabino J, Savarino E, Stassen L, Torres J, Uzzan M, Vavricka S, Verstockt B, Zmora O. ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. *J Crohns Colitis* 2020; **14**: 155-168 [PMID: 31742338 DOI: 10.1093/ecco-jcc/jjz187]

**Footnotes**

**Institutional review board statement:** According to the Ethics Committee of the Bavarian State Chamber of Physicians retrospective reviews of anonymized patient data do not require ethical approval, No. 2021-1022.

**Informed consent statement:** Patients were not required to give informed consent to the study because the retrospective analysis used anonymized clinical data that were obtained after each patient agreed to treatment by written consent.

**Conflict-of-interest statement:** The author had honoraria from Takeda and Medtronic for invited presentations during advisory board meetings and satellite symposia. Neither funding nor financial support was administered for the current study.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** January 9, 2021

**First decision:** January 23, 2021

**Article in press:** June 4, 2021

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Germany

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Pelletier AL, Yuksel I, Zhao L **S-Editor:** Fan JR **L-Editor:** A **P-Editor:** Wang LL

**Table 1** **Inclusion and exclusion criteria for administration of darvadstrocel**

|  |  |
| --- | --- |
| **Inclusion** | **Exclusion** |
| Complex anal fistulas associated with Crohn’s disease (including hors-shoe fistula) | Simple fistulas associated with Crohn’s disease, rectovaginal fistula |
| At least one conventional, biological or surgical therapy prior to stem cell injection | No medical, biological or surgical therapy prior to stem cell injection |
| No active Crohn’s disease confirmed by ileocolonoscopy | Active Crohn’s disease confirmed by ileocolonoscopy |
| No perianal abscess or sepsis confirmed by clinical exam, endoanal ultrasound and/or pelvic MRI | Perianal abscess or significant inflammation in the pelvis or anorectal region confirmed by MRI |
| Interdisciplinary recommendation | No recommendation by multidisciplinary team |
| Patient compliant for medical consultation, follow-up examination and interdisciplinary monitoring of disease | Non-compliance of patient |
| Pretreatment of fistulas by seton drainage (“conditioning”) | Fistulas without seton drainage or conditioning by curretage |
| Maximum of two fistulas with two internal and two external openings (each) | More than two complex fistulas |
| No anorectal stenosis | Presence of anorectal stenosis |
| Fully informed consent possible | No informed consent possible |

MRI: Magnetic resonance imaging.

**Table 2** **Definitions of outcome**

|  |  |  |
| --- | --- | --- |
| **Parameter** | **Definition** | **Supplementary definition** |
| Healing | Complete healing of internal and external opening; no abscess, no symptoms | Assessment by clinical examination including proctoscopy |
| Persistence | No complete healing with persistence of fistula (external opening) and/or symptoms | Defined postoperative observation period |
| Recurrence | Recurrence of fistula after period with complete healing and interval without symptoms | With or without occurrence of abscess |

**Table 3 Patients’ population**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **1** | **2** | **3** | **4** | **5** | **6** | **7** | **8** | **9** | **10** | **11** |
| Age (yr) | 26  | 31 | 52 | 49 | 39 | 35 | 61 | 26 | 54 | 44 | 45 |
| Gender | Male | Female | Female | Female | Male | Female | Male | Female | Male | Male | Male |
| CD diagnosis | 2011 | 2005 | 1992 | 1991 | 2008 | 2002 | 1984 | 2012 | 1988 | 2006 | 2000 |
| CD actual medical treatment | Adalimumab | Ustekinumab | Azathioprin | None | Ustekinumab | Vedolizumab | Ustekinumab | Infliximab | Infliximab | Infliximab | Adalimumab |
| CPF diagnosis date | 2017 | 2011 | 2018 | 2017 | 2009 | 2007 | 2006 | 2012 | 2013 | 2006 | 2004 |
| CPF diagnosis method | Clinical + MRI | Clinical + MRI | Clinical | Clinical + MRI | Clinical | Clinical | Clinical | Clinical + MRI | Clinical + MRI | Clinical + MRI | Clinical + EAUS |
| CPF classification (Parks) | Transsphincteric (two fistula) | Transsphincteric (two fistula) | Suprasphincteric (one fistula) | Transsphincteric (two fistula | TranssphinctericIntersphincteric (two fistula) | Transsphincteric (two fistula) | Transsphincteric (two fistula) | Transsphincteric (1) | Suprasphincteric (1) transsphincteric (1) | Transsphincteric (1), subcutaneous (1); horse-shoe-fistula | Transsphincteric (1), subcutaneous (1), horse-shoe-fistula |
| Number of internal/external openings | 2/2 | 2/2 | 1/1 | 2/2 | 2/2 | 1/2 | 2/2 | 1/1 | 2/2 | 1/2 | 1/2 |
| Length of fistula tract | 3 cm each | 3 cm each | 4 cm | 2 cm; 5 cm | 10 cm; 1.5 cm | 12 cm; 1.5 cm | 3 cm; 7 cm | 3 cm | 6.5 cm; 2.5 cm | 2.5 cm; 2.5 cm | 3.0 cm; 3.0 cm |
| Previous treatment (medical) | Azathioprin | AzathioprinInfliximab | Azathioprin | Azathioprin | Azathioprin | Azathioprin | AzathioprinInfliximab | Azathioprin | Adalimumab | AzathioprinAdalimumab | Infliximab |
| Previous treatment (surgical) | Multiple abscess excisions, one previous fistula surgery | Multiple abscess excisions, one previous fistula surgery | Multiple abscess excisions, threeprevious fistula surgery | Multiple abscess excisions, two previous fistula surgery | Multiple abscess excisions, three previous fistula surgery | Multiple abscess excisions, two previous fistula surgery | Multiple abscess and fistula surgeries (11) | Multiple abscess and fistula surgery (4) | Multiple abscess and fistula surgery (4) | Multiple abscess and fistula surgery (4) | Multiple abscess and fistula surgery (3) |
| Previous treatment (stoma) | No | Yes | No | Yes | No | No | No | No | No | Yes | Yes |
| Seton drainage prior to Darvastrocel (duration) | Yes (6 wk) | Yes (4 mo) | Yes (10 mo) | Yes (18 mo) | Yes (8 wk) | Yes (12 wk) | Yes (9 mo) | Yes (60 wk) | Yes (36 wk) | Yes (48 wk) | Yes (24 wk) |
| Curretage performed (prior to/day of Darvastrocel administration) | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Method of closure of internal opening | Suture (1), mucosal flap (1) | Suture (2) | Suture (1) | Suture (2) | Suture (2) | Suture (1) | Suture (2) | Suture (1) | Suture (2) | Suture (1) | Suture (1) |
| Intraoperative difficulties/adverse events | No | No | No | No | No | No | No | No | No | No | No |
| Postoperative morbidity/SAE | No | No | No | No | No | No | No | No | No | No | Fewer (day 2) |

CD: Crohn’s disease; BMI: Body mass index; CPF: Crohn’s perianal fistula; SAE: Serious adverse events; EAUS: Endoanal ultrasound; MRI: Magnetic resonance imaging.

**Table 4** **Efficacy evaluation and outcomes**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **1** | **2** | **3** | **4** | **5** | **6** | **7** | **8** | **9** | **10** | **11** |
| Length of follow-up (mo) | 27 | 27 | 8 | 24 | 26 | 12  | 17 | 6 | 6  | 3 | 3 |
| Efficacy evaluation (clinical) | Complete healing | Complete healing | Complete healing | Recurrence | Persistence | Complete healing | Complete healing | Complete healing | Persistence | Complete healing | Recurrence |
| Efficacy evaluation (MRI) | Not performed | Complete healing | Not performed | Recurrence | Persistence | Not performed | Not performed | Not performed | Not performed | Not performed | Not performed |
| Overall outcome (clinical remission/healing) | Complete healing | Complete healing | Complete healing | Recurrence | Persistence  | Complete healing | Complete healing | Complete healing | Persistence | Complete healing | Recurrence |
| Time to fistula closure | 6 wk | 12 wk | 9 wk | - | - | 12 wk | 30 wk | 9 wk | - | 9 wk | - |
| Incidence of abscess during follow-up | Yes (twice; 9 and 22 mo postop.) | No | No | No | Yes (9 mo postop.) | No | Yes | No | Yes (4 mo postop.) | No | Yes (3 mo postop.) |
| Further surgery during follow-up | Yes, Abscess excision (twice) | No | No | Stoma revision, seton drainage | Yes, Abscess excision | No | No | No | Yes, Abscess excision | No | Yes, Abscess excision |
| Maintenance therapy | Adalimumab | Ustekinumab | Azathioprin | Infliximab | Ustekinumab | Vedolizumab | Ustekinumab | ceased | Infliximab | Infliximab | Adalimumab |
| Stoma reversal (if present) | No stoma | Stoma reversal | No stoma | No | No stoma | No stoma | No stoma | No stoma | No stoma | No | No |

MRI: Magnetic resonance imaging.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**